Thrombocytosis During Antifungal Therapy of Candidemia

Saathoff, Angela; Elkins, S.; Chapman, Stanley W.; McAllister, Susan Fleming; Cleary, John D.

doi:10.1345/aph.1e402

Cited by 8 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, extreme thrombocytosis has rarely been reported (Table 1). In a study of antifungal therapy [9], a maximum peak platelet count of 1056,000/ll was observed in a 27-year-old female with baseline platelet values of 200,000/ll after 14 days of antifungal therapy with unknown agent for candidemia. The onset of thrombocytosis in this patient was 4 days into therapy and lasted 4 days after therapy.…”

Section: Discussionmentioning

confidence: 98%

Marked thrombocytosis during treatment with ceftazidime for pulmonary infection

Chen

Wang

2007

Pharm World Sci

View full text Add to dashboard Cite

When an infected patient suffers from thrombocytosis, it is very difficult to identify beta-lactam antibiotic induced cases of the disease and separate these from the possibility that the disease is an acute-phase reaction in the infected patient. We present the case of a 54-year-old man who was treated with ceftazidime for pneumonia and developed thrombocytosis during the treatment course. Thrombocytosis persisted until ceftazidime was discontinued, despite clinical and radiological evidence showing that the pneumonia had greatly improved. The Naranjo probability scale indicates ceftazidime as the possible cause of the thrombocytosis in our patient. Although no obvious complications occur in most patients, we should pay close attention to the possibility of adverse reactions and evaluate whether the infection is treated with the appropriate antibiotics.

show abstract

Section: Discussionmentioning

confidence: 98%

Marked thrombocytosis during treatment with ceftazidime for pulmonary infection

Chen

Wang

2007

Pharm World Sci

View full text Add to dashboard Cite

show abstract

“…However, extreme thrombocytosis has been rarely reported. In a study of antifungal therapy [9], a patient was noted as having extremely high thrombocytosis, up to 1,056 · 10 9 /l, on the forth day after treatment and lasted 4 days after therapy.…”

Section: Discussionmentioning

confidence: 99%

Extreme thrombocytosis under the treatment by amoxicillin/clavulanate

et al. 2006

View full text Add to dashboard Cite

Amoxicillin/Clavulanate related extreme thrombocytosis during the treatment of pneumonia has never been reported. We present a 54-year-old patient who was admitted due to pneumonia, and was treated with amoxicillin/clavulanate IV and 3-day course of 500 mg azithromycin. Despite clinical and radiological evidence showing that pneumonia improved, thrombocytes increased rapidly. After stopping the antibiotic, the thrombocytes returned gradually to normal. Considering the clinical course, we propose that this extreme thrombocytosis was caused by the administration of amoxicillin/clavulanate. We describe this rare and unique patient and review the literature.

show abstract

“…Nonhematological cancer (e.g., esophageal [11], dermatologic [4], liver [5,6]), or cancer therapy [12] Iron deficiency [12] Associated with shorter-term thrombocytosis Surgical asplenia [12] Infection Hemolysis Bleeding [12] Trauma [12,13] Medications (e.g., antifungals [14], ciprofloxacin and tazobactam/ piperacillin [15], amoxicillin/clavulanate [16], enoxaparin [17]) most often due to infection and iron deficiency (50% and 24% of the group with elevated platelets, respectively) [30]. These data did not separate in-patients and outpatients.…”

Section: Platelet Counts and Risk Assessmentmentioning

confidence: 99%

Thrombocytosis in the NICU

Powner

Hoots

2008

Neurocrit Care

View full text Add to dashboard Cite

An elevated platelet count may occur during care of neurology/neurosurgical patients and is usually due to reactive or secondary thrombocytosis (ST) caused by inflammation or infection. Primary (clonal) thrombocythemia or essential thrombocythemia associated with myeloproliferative disorders is usually known before or during early patient assessment. Rarely, paraneoplastic causes of thrombocytosis may be discovered. Although no single test differentiates primary from secondary etiologies, laboratory tests that show increased acute phase responses, such as C-reactive protein, fibrinogen, erythrocyte sedimentation rate, and interleukin-6, may be useful in diagnosing ST. Thrombosis due to ST is rare in any platelet count. ST, however, should be considered within the overall risk assessment for thromboembolism in any patient. If treatment is initiated, low-dose aspirin is sufficient.

show abstract

Thrombocytosis During Antifungal Therapy of Candidemia

Abstract: Reactive thrombocytosis occurs during treatment of candidemia. The causative agent (drug vs disease), the risk associated with this reaction, and evaluation of treatment need to be elucidated by a larger epidemiologic study or controlled, prospective clinical trial.

Cited by 8 publications

References 20 publications

Marked thrombocytosis during treatment with ceftazidime for pulmonary infection

Marked thrombocytosis during treatment with ceftazidime for pulmonary infection

Extreme thrombocytosis under the treatment by amoxicillin/clavulanate

Thrombocytosis in the NICU

Contact Info

Product

Resources

About